Abbott Laboratories has reported better-than-expected first-quarter earnings, with worldwide sales increasing 2.2% year over year to approximately $10 billion. Organic sales growth for the underlying base business also saw strong growth of 10.8% year over year. The performance was broad-based, with Abbott’s Medical Devices segment leading the way with a 14.3% increase in sales. Following the strong quarter, Abbott raised the low end of its full-year adjusted EPS and organic sales outlooks, which is seen as a positive sign for the company’s performance moving forward.
Jim Cramer’s Charitable Trust plans to buy 100 shares of Abbott Laboratories at approximately $108.26, increasing its ownership to a total of 800 shares. This will bring the trust’s weighting in ABT to roughly 2.8% from 2.45%. Despite the positive earnings report, Abbott’s stock is trading lower in the premarket, presenting an opportunity for the trust to add to its position for the third time in recent weeks. The trust initiated its Abbott stake in late January, with additional purchases made in March. This decision to increase the position reflects confidence in Abbott’s underlying business performance and the company’s outlook for the year.
The trust believes that Abbott’s raised full-year outlook, especially at the low end of the guidance range, is indicative of a strong year ahead for the company. The focus on analyzing the underlying business, which excludes Covid-19 testing-related sales, is considered essential in evaluating Abbott’s performance. While the stock has experienced a slight decline year to date, the trust sees this as an opportunity to capitalize on the weakness in the market following a strong quarter. By adding to their position, the trust aims to leverage the potential growth and performance of Abbott Laboratories in the coming months.
As a subscriber to the CNBC Investing Club with Jim Cramer, members receive trade alerts before Jim makes a trade. Jim follows a specific protocol, waiting 45 minutes after sending a trade alert before executing a trade for his charitable trust. If Jim has discussed a stock on CNBC TV, he waits 72 hours after issuing the trade alert before making a trade. These measures aim to ensure transparency and fairness in the trading process. The information provided by the Investing Club is subject to terms and conditions, privacy policy, and disclaimer, with no fiduciary obligation or duty created by receiving the information.
In conclusion, the decision by Jim Cramer’s Charitable Trust to increase its position in Abbott Laboratories reflects confidence in the company’s strong first-quarter performance and raised outlook for the full year. The focus on analyzing the underlying business performance, excluding Covid-19 related sales, is seen as a key factor in evaluating Abbott’s growth potential. Despite the stock trading lower in the premarket, the trust views this as an opportunity to capitalize on the market weakness following a positive earnings report. By strategically adding to their position, the trust aims to benefit from Abbott’s anticipated performance and growth in the coming months.
